


**Company Registration No. 02892098**

**Infectious Music Limited**

**Reports and Financial Statements**

**31 December 2019**

WEDNESDAY



\*A913UC6J\*

A04

18/03/2020

#110

COMPANIES HOUSE

# **Infectious Music Limited**

## **Reports and Financial Statements 2019**

<b>Contents</b>	<b>Page</b>
<b>Officers and professional advisers</b>	<b>1</b>
<b>Strategic report</b>	<b>2</b>
<b>Directors' report</b>	<b>3</b>
<b>Statement of directors' responsibilities in respect of the financial statements</b>	<b>5</b>
<b>Independent auditors' report</b>	<b>6</b>
<b>Statement of comprehensive income</b>	<b>9</b>
<b>Statement of financial position</b>	<b>10</b>
<b>Statement of changes in equity</b>	<b>11</b>
<b>Statement of cash flows</b>	<b>12</b>
<b>Notes to the financial statements</b>	<b>13</b>

# **Infectious Music Limited**

## **Reports and financial statements 2019**

### **Officers and professional advisers**

#### **Directors**

Jonathan Baker  
David D'Urbano  
Maximilian Dressendörfer  
Benjamin Katovsky  
Hartwig Masuch  
Alistair Norbury

#### **Registered Office**

8<sup>th</sup> Floor  
5 Merchant Square  
London  
United Kingdom  
W2 1AS

#### **Independent Auditors**

PricewaterhouseCoopers LLP  
Chartered Accountants and Statutory Auditors  
1 Embankment Place  
London  
WC2N 6RH

# **Infectious Music Limited**

## **Strategic report**

The directors present their Strategic report for the year ended 31 December 2019 for Infectious Music Limited (the "Company").

### **Business review**

The Company is a wholly-owned United Kingdom subsidiary of BMG Rights Management (UK) Limited. The Company owns and administers rights to musical compositions, exploits and markets these compositions and receives royalties or fees for their use.

### **Strategy**

The Company is part of an international group of companies focused on the management of music rights. The Company covers the entire range of rights administration, development and exploitation, placing the needs of songwriters and artists at the core of its business model. At the core of the Company's strategy is delivering a high quality rights administration service to artists and writers.

### **Key performance indicators**

The directors monitor the Company's performance in a number of ways including key performance indicators such as reported revenue, gross profit and operating profit, Earnings Before Interest and Taxes; ("EBIT") and EBITDA (as adjusted for depreciation and amortisation). The Company is financed through intercompany funding from its group parent companies and through equity. The Company continues to perform in line with expectations.

### **Business performance**

As shown in the Company's Statement of comprehensive income on page 9, the Company reported revenues for the year of £1,851,000 (2018: £1,940,000) and gross profit of £688,000 (2018: £752,000). Profit from operations was £168,000 (2018: £168,000).

The Company reported EBITDA of £168,000 (2018: £168,000).

The net assets as at 31 December 2019 were £377,000 (2018: £224,000).

### **Principal risks and uncertainties**

From the perspective of the Company, the principal risks and uncertainties are integrated with the principal risks of BMG Rights Management (UK) Limited and its subsidiaries and are not managed separately. Accordingly, the principal risks and uncertainties of BMG Rights Management (UK) Limited, which include those of the Company, are discussed in those financial statements and does not form part of this report. BMG Rights Management (UK) Limited's financial statements are publicly available and can be accessed at Companies House.

Approved by the Board of Directors  
and signed on behalf of the Board



David D'Urbano  
Director  
11 March 2020

# **Infectious Music Limited**

## **Directors' report**

The directors present their Directors' report and audited financial statements for the year ended 31 December 2019 for Infectious Music Limited (the "Company").

### **Principal activities**

The principal business of the Company during the year ended 31 December 2019 was the production and sale of all forms of recorded music.

### **Outlook**

The directors do not anticipate any significant change in the activities of the Company.

### **Financial instruments**

Exposure to credit, liquidity, interest rate and currency risks arises in the normal course of the Company's business. The Company's exposure to financial instruments are discussed in the notes to the financial statements under the heading "Financial instruments".

### **Going concern**

After making enquiries, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Further details regarding the adoption of the going concern basis can be found in Note 1 to the financial statements.

### **Directors**

The directors of the Company who were in office during the year and up to the date of signing the financial statements were as follows:

Jonathan Baker  
David D'Urbano (appointed on 1 May 2019)  
Maximilian Dressendörfer  
Benjamin Katovsky  
Korda Marshall (resigned on 10 February 2020)  
Hartwig Masuch  
Alistair Norbury  
Paul Wilson (resigned on 10 May 2019)

### **Dividends**

The directors do not recommend a dividend for the year (2018: £nil).

# **Infectious Music Limited**

## **Directors' report (continued)**

### **Political and charitable contributions**

The Company made no political or charitable contributions or incurred any political expenditure during the current or prior year.

### **Independent Auditors**

The financial statements have been audited by PricewaterhouseCoopers LLP, who retire following the audit of these statutory financial statements.

Approved by the Board of Directors  
and signed on behalf of the Board

A handwritten signature in black ink, appearing to be 'D'Urbano', written over a horizontal line.

David D'Urbano

Director

11 March 2020

## **Infectious Music Limited**

### **Statement of directors' responsibilities in respect of the financial statements**

The directors are responsible for preparing the Reports and Financial Statements in accordance with applicable law and regulation.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have prepared the financial statements in accordance with International Financial Reporting Standards (IFRSs) as adopted by the European Union. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing the financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- state whether applicable IFRSs as adopted by the European Union have been followed, subject to any material departures disclosed and explained in the financial statements;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.


The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006.

#### **Directors' confirmations**

In the case of each director in office at the date the Director's report is approved:

- so far as the director is aware, there is no relevant audit information of which the Company's auditors are unaware; and
- they have taken all the steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the Company's auditors are aware of that information.

Approved by the Board of Directors  
and signed on behalf of the Board



David D'Urbano  
Director  
11 March 2020

# **Infectious Music Limited**

## **Independent auditors' report to the members of Infectious Music Limited (continued)**

### **Report on the audit of the financial statements**

#### **Opinion**

In our opinion, Infectious Music Limited's financial statements:

- give a true and fair view of the state of the Company's affairs as at 31 December 2019 and of its profit and cash flows for the year then ended;
- have been properly prepared in accordance with International Financial Reporting Standards (IFRSs) as adopted by the European Union; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements, included within the Reports and Financial Statements (the "Annual Report"), which comprise: the Statement of financial position as at 31 December 2019; the Statement of comprehensive income; the Statement of cash flows, and the Statement of changes in equity for the year then ended; and the notes to the financial statements, which include a description of the significant accounting policies.

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### *Independence*

We remained independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

#### **Conclusions relating to going concern**

ISAs (UK) require us to report to you when:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the Company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

We have nothing to report in respect of the above matters.

However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Company's ability to continue as a going concern. For example, the terms of the United Kingdom's withdrawal from the European Union are not clear, and it is difficult to evaluate all of the potential implications on the Company's trade, customers, suppliers and the wider economy.

#### **Reporting on other information**

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.



# **Infectious Music Limited**

## **Independent auditors' report to the members of Infectious Music Limited (continued)**

### **Reporting on other information (continued)**

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Strategic report and Directors' report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on the responsibilities described above and our work undertaken in the course of the audit, ISAs (UK) require us also to report certain opinions and matters as described below.

#### *Strategic report and Directors' report*

In our opinion, based on the work undertaken in the course of the audit, the information given in the Strategic report and Directors' report for the year ended 31 December 2019 is consistent with the financial statements and has been prepared in accordance with applicable legal requirements.

In light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we did not identify any material misstatements in the Strategic report and Directors' report.

### **Responsibilities for the financial statements and the audit**

#### *Responsibilities of the directors for the financial statements*

As explained more fully in the Statement of directors' responsibilities in respect of the financial statements set out on page 5, the directors are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The directors are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

#### *Auditors' responsibilities for the audit of the financial statements*

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our auditors' report.

## **Infectious Music Limited**

### **Independent auditors' report to the members of Infectious Music Limited (continued)**

#### *Use of this report*

This report, including the opinions, has been prepared for and only for the Company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

#### **Other required reporting**

##### **Companies Act 2006 exception reporting**

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- we have not received all the information and explanations we require for our audit; or
- adequate accounting records have not been kept by the Company, or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of directors' remuneration specified by law are not made; or
- the financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.



Jonathan Ford (Senior Statutory Auditor)  
for and on behalf of PricewaterhouseCoopers LLP  
Chartered Accountants and Statutory Auditors  
London

11 March 2020

## Infectious Music Limited

### Statement of comprehensive income for the year ended 31 December 2019

		Year ended 31 December 2019 £'000	Year ended 31 December 2018 £'000
	<b>Note</b>		
<b>Continuing operations</b>			
Revenue	2	1,851	1,940
Cost of sales		(1,163)	(1,188)
		<hr/>	<hr/>
<b>Gross profit</b>		688	752
Administrative expenses		(520)	(584)
		<hr/>	<hr/>
<b>Profit from operations</b>	3	168	168
Finance costs	5	(2)	(8)
Finance income	5	1	-
		<hr/>	<hr/>
<b>Profit before taxation</b>		167	160
Taxation	6	(14)	(15)
		<hr/>	<hr/>
<b>Profit and total comprehensive income for the year</b>		<u>153</u>	<u>145</u>

The accompanying notes on pages 13 to 24 are an integral part of this Statement of comprehensive income.  
All results relate to continuing operations.

# Infectious Music Limited


## Statement of financial position as at 31 December 2019

	Note	2019 £'000	Restated 2018 £'000
<b>Current assets</b>			
Trade and other receivables	7	1,599	1,551
<b>Total current assets</b>		<u>1,599</u>	<u>1,551</u>
<b>Total assets</b>		<u>1,599</u>	<u>1,551</u>
<b>Current liabilities</b>			
Trade and other payables	8	(1,222)	(1,327)
<b>Total current liabilities</b>		<u>(1,222)</u>	<u>(1,327)</u>
<b>Net assets</b>		<u>377</u>	<u>224</u>
<b>Equity</b>			
Share capital	9	-	-
Retained earnings		377	224
<b>Total equity</b>		<u>377</u>	<u>224</u>

The accompanying notes on pages 13 to 24 are an integral part of this Statement of financial position.

The financial statements, on pages 9 to 24, of Infectious Music Limited, registered number 02892098, were approved by the Board of Directors on 11 March 2020.

Signed on behalf of the Board of Directors



David D'Urbano  
Director

# Infectious Music Limited

## Statement of changes in equity for the year ended 31 December 2019

	Note	Share capital £'000	Share Premium £'000	(Accumulated losses) / retained earnings £'000	Total equity £'000
As at 1 January 2018		1	-	(172)	(171)
Profit and total comprehensive income for the year		-	-	145	145
Share issue	9	-	250	-	250
Capital reduction	9	(1)	(250)	251	-
As at 31 December 2018		-	-	224	224
Profit and total comprehensive income for the year		-	-	153	153
As at 31 December 2019		-	-	377	377

The accompanying notes on pages 13 to 24 are an integral part of this Statement of changes in equity.

# Infectious Music Limited

## Statement of cash flows for the year ended 31 December 2019

	Year ended 31 December 2019 £'000	Restated Year ended 31 December 2018 £'000
<b>Cash flows from operating activities</b>		
Profit before taxation	167	160
Adjustment for:		
Movement in provisions	5	(17)
Finance income	(1)	-
Finance costs	2	8
	<hr/>	<hr/>
Operating profit before movements in working capital	173	151
Decrease in receivables	46	2,361
Decrease in payables	(197)	(2,841)
Tax (paid)/received	(21)	87
	<hr/>	<hr/>
Cash used in operations	(172)	(393)
	<hr/>	<hr/>
<b>Net cash generated from/(used in) operating activities</b>	<u>1</u>	<u>(242)</u>
<b>Cash flows from financing activities</b>		
Finance costs	(2)	(8)
Finance income	1	-
Proceeds from share issue	-	250
	<hr/>	<hr/>
<b>Net cash (used in)/generated from financing activities</b>	<u>(1)</u>	<u>242</u>
<b>Net change in cash and cash equivalents</b>	-	-
Cash and cash equivalents at the beginning of the year	-	-
	<hr/>	<hr/>
<b>Cash and cash equivalents at the end of the year</b>	<u>-</u>	<u>-</u>

The accompanying notes on pages to 13 to 24 are an integral part of this Statement of cash flows

# Infectious Music Limited

## Notes to the financial statements Year ended 31 December 2019

### 1. Accounting policies

Infectious Music Limited (the "Company") is a private company limited by shares and incorporated in England and Wales. The address of its registered office is 8<sup>th</sup> Floor, 5 Merchant Square, London, United Kingdom, W2 1AS.

The financial statements have been restated for the year ended 31 December 2018 to incorporate the impact of an advances adjustment that was erroneously posted.

At 31 December 2018, this resulted in a increase of trade and other receivables of £806,000 and a increase in trade and other payables of £806,000.

The accounting policies set out below have, unless otherwise stated, been applied consistently to all periods presented in these financial statements.

#### **Basis of preparation**

The financial statements are presented in pounds sterling, rounded to the nearest thousand. They are prepared on the historical cost basis except for financial instruments which are recognised as per the measurement convention below.

The financial statements have been prepared in accordance with Companies Act 2006 and European Union ("EU") adopted International Financial Reporting Standards ("IFRS") and interpretations issued by the IFRS Interpretations Committee (IFRS IC) applicable to companies reporting under IFRS.

The preparation of financial statements in conformity with IFRS which requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the year in which the estimate is revised if the revision affects only that year or in the year of the revision and future years if the revision affects both current and future years.

#### **Measurement convention**

The financial statements are prepared on the historical cost basis except financial instruments classified as fair value through the profit or loss. Non-current assets are stated at the lower of carrying amount and fair value less costs to sell.

#### **Going concern**

The Company's business activities, together with the factors likely to affect its future development, performance and position are set out in the Strategic report and the Directors' report on pages 2 to 4. The directors have considered the financial resources available along with the future plans for the Company when considering the going concern of the Company. After making enquiries, the directors have a reasonable expectation that the Company will have access to adequate resources from its parent company, to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

#### **Foreign currency**

Transactions in foreign currencies are translated to the Company's functional currency at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Statement of financial position date are translated at the foreign exchange rate ruling at that date. Foreign exchange differences arising on translation are recognised in the Statement of comprehensive income. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Non-monetary assets and liabilities denominated in foreign currencies that are stated at fair value are translated at foreign exchange rates ruling at the dates the fair value was determined.

# **Infectious Music Limited**

## **Notes to the financial statements (continued)**

### **Year ended 31 December 2019**

#### **1. Accounting policies (continued)**

##### **Impairment excluding inventories and deferred tax assets**

The carrying amounts of the Company's assets are reviewed at each Statement of financial position date to determine whether there is any indication of impairment. If any such indication exists, the asset's recoverable amount is estimated.

An impairment loss is recognised whenever the carrying amount of an asset exceeds its recoverable amount. Impairment losses are recognised in the Statement of comprehensive income.

##### **Calculation of recoverable amount**

The recoverable amount of the Company's receivables earned at amortised cost is calculated as the present value of estimated future cash flows, discounted at the original effective interest rate (i.e. the effective interest rate computed at initial recognition of these financial assets). Receivables with a short duration are not discounted.

The recoverable amount of other assets is the greater of their net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash-generating unit to which the asset belongs.

##### **Reversal of impairment**

An impairment loss in respect of receivables earned at amortised cost is reversed if the subsequent increase in recoverable amount can be related objectively to an event occurring after the impairment loss was recognised.

An impairment loss in respect of goodwill is not reversed.

In respect of other assets, an impairment loss is reversed when there is an indication that the impairment loss may no longer exist and there has been a change in the estimates used to determine the recoverable amount.

An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

##### **Cash and cash equivalents**

Cash and cash equivalents comprise cash balances and call deposits. Bank overdrafts that are repayable on demand and form an integral part of the Company's cash management are included as a component of cash and cash equivalents for the purpose only of the Statement of cash flows.

##### **Loan receivables and payables**

Long term loans are measured at fair value net of transaction costs.

##### **Trade and other receivables**

Trade and other receivables to group companies include the group cash pooling financing facility with the parent company in Germany. The facility earns interest at a margin of 0.125% less the Bank of England base rate. Trade and other receivables at the Statement of financial position date are stated at amortised cost which approximates to cost less impairment losses.



# Infectious Music Limited

## Notes to the financial statements (continued) Year ended 31 December 2019

### 1. Accounting policies (continued)

#### **Investments and other financial assets**

The Company measures its financial assets at amortised cost. The Company's financial assets consist of trade receivables and long-term loans receivable.

Financial assets are recognised on the trade date (the date the Company commits to purchase or sell the asset) and derecognised when the rights to receive cash flows from the financial assets have expired or the risks and rewards of ownership of those rights have been transferred to another party.

The Company measures a financial asset at the amount recognised at initial recognition minus principal repayments, plus or minus the cumulative amortisation of any difference between the initial amount and the maturity amount, and any loss allowance. Interest income is calculated using the effective interest method and is recognised in profit and loss. Changes in fair value are recognised in profit and loss when the asset is derecognised or reclassified.

#### *Impairment*

The Company assesses the expected credit losses associated with its financial assets carried at amortised cost.

The Company applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

#### **Trade and other payables**

Trade and other payables to group companies include the group cash pooling financing facility with the parent company in Germany. The facility bears interest at a margin of 1.25% above the Bank of England base rate. Trade and other payables at the Statement of financial position date are stated at amortised costs which approximates to cost less impairment.

#### **Revenue**

Revenue is measured at the fair value of the consideration receivable and represents amounts receivable for services provided in the normal course of business, net of discounts and value added tax.

Revenue from royalty licensing is recognised in accordance with IFRS 15. According to IFRS 15, revenue from royalties shall be recognised when it is probable that the economic benefits associated with the transaction will flow to the Company, the amount of the revenue can be measured reliably, and it is highly probable the revenue will not be reversed. Where revenue streams have a forward visibility revenue is recognised on an accruals basis. If there is no or minimal forward visibility of revenue streams it is not possible to measure the revenue streams reliably until cash is collected.

#### **Master record royalties**

Record royalties derived from the exploitation of the Company's master record rights are included on a receivable and/or due basis calculated on sales of records arising during each accounting year as reported by licensees. Based on the matching principle, royalties payable are accrued at the time the revenue is recognised.

Where the Company receives advances which are recoupable from future sales or profits, or are otherwise conditional on continued performance of duties by the Company, these are recorded as liabilities. Revenue is recognised as it is earned. Advance payments to artists are carried forward within other receivables where they relate to proven artists and where it is estimated that sufficient future income will be recouped against those advance payments.

Advance payments should be written off if these are not covered by future income. In case of unproven contract, the advance payments should be immediately written off. Any other royalty licensing income is recognised on a cash basis.

# **Infectious Music Limited**

## **Notes to the financial statements (continued)** **Year ended 31 December 2019**

### **1. Accounting policies (continued)**

#### **Net financing costs**

Net financing costs comprise interest payable and interest receivable on funds invested. Interest income and interest payable is recognised in profit or loss as it accrues, using the effective interest method.

#### **Taxation**

Current tax for the year comprises current and deferred tax. Tax is recognised in the Statement of comprehensive income except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity.

Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted or substantively enacted at the Statement of financial position date, and any adjustment to tax payable in respect of previous years.

Deferred tax is provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the Statement of financial position date. A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the asset can be utilised.

#### **Critical accounting judgements and key sources of estimation uncertainty**

The following are the critical judgements, apart from those involving estimations (which are dealt with separately below), that the directors have made in the process of applying the group's accounting policies and that have the most significant effect on the amounts recognised in financial statements.

The Company uses estimates to calculate the writer royalties due for the second half of the year for all the royalty receipts and industry standard rates to estimate the royalty accruals.

Writer advances provisions were made during the year based on a recoupment profile calculation used by BMG Rights Management (UK) Limited and its subsidiaries.

#### **New standards, amendments and interpretations**

##### ***IFRS 16 Leases***

IFRS 16 Leases has replaced IAS 17 Leases for annual periods beginning on or after 1 January 2019.

IFRS 16 Leases provides a single lessee accounting model, requiring the recognition of assets and liabilities for all leases, together with options to exclude leases where the lease term is 12 months or less, or where the underlying asset is of low value. IFRS 16 Leases substantially carries forward the lessor accounting in IAS 17, with the distinction between operating leases and finance leases being retained. The Company does not have significant leasing activities as a lessee or lessor.

No other new standards, amendments or interpretations, effective for the first time for the financial year beginning on or after 1 January 2019, have had a material impact on the Company.

# Infectious Music Limited

## Notes to the financial statements (continued) Year ended 31 December 2019

### 2. Revenue

An analysis of the Company's revenue is as follows:

	Year ended 31 December 2019 £'000	Year ended 31 December 2018 £'000
<b>Geographical Market</b>		
United Kingdom	1,650	1,928
North America	173	6
Europe	27	-
Other	1	6
	<u>1,851</u>	<u>1,940</u>

The operations of the Company take place wholly in the United Kingdom. Revenue was derived from the principal activity conducted within the United Kingdom. All assets used by the Company are held in the United Kingdom.

### 3. Profit from operations

Profit from operations has been arrived at after charging:

	Year ended 31 December 2019 £'000	Year ended 31 December 2018 £'000
Management fees	511	589
Movement in provisions	5	-
Net foreign exchange loss	1	16
	<u>517</u>	<u>605</u>

The audit fee of £8,000 (2018: £8,000) was borne by BMG Rights Management Services (UK) Limited.

### 4. Employee costs and directors' emoluments

The number of staff employed by the Company is nil (2018: nil), therefore no costs were incurred in either year. The directors did not receive emoluments in respect of their services to the Company (2018: £nil). Their emoluments were borne by affiliate company BMG Rights Management Services (UK) Limited. Costs were recharged to the Company as part of management fees.

# Infectious Music Limited

## Notes to the financial statements (continued) Year ended 31 December 2019

### 5. Finance cost/income

	Year ended 31 December 2019 £'000	Year ended 31 December 2018 £'000
Finance cost	(2)	(8)
Finance income	1	-
	<u>(1)</u>	<u>(8)</u>

Interest expense represents interest charged from the parent company and other related parties in respect of cash pooling and loan facilities provided.

### 6. Taxation

	Year ended 31 December 2019 £'000	Year ended 31 December 2018 £'000
<b>Current taxation</b>		
Foreign tax charge	8	-
Double tax relief	(8)	-
UK corporation tax - current year	16	15
UK corporation tax – prior year	(2)	-
	<u>14</u>	<u>15</u>
<b>Current tax charge</b>		
	<u>14</u>	<u>15</u>
<b>Deferred taxation</b>		
UK deferred tax – current year	-	-
	<u>-</u>	<u>-</u>
<b>Total tax charge</b>	<u>14</u>	<u>15</u>

The tax assessed for both years differs from the standard effective rate of corporation tax in the UK for the year ended 31 December 2019 of 19% (2018: 19%). The differences are explained below:

#### Tax reconciliation

	Year ended 31 December 2019 £'000	Year ended 31 December 2018 £'000
Profit before taxation	167	160
Tax at 19% (2018: 19%)	32	30
Effects of:		
Utilisation of previously unrecognised losses	(16)	(15)
UK corporation tax – prior year	(2)	-
	<u>14</u>	<u>15</u>
<b>Total tax charge</b>	<u>14</u>	<u>15</u>

# Infectious Music Limited

## Notes to the financial statements (continued) Year ended 31 December 2019

### 6. Taxation (continued)

The Company has a deferred tax asset in relation to losses of £290,000 (2018: £302,000) which has not been recognised because there is currently insufficient evidence that suitable profits will be generated to offset the future reversal of these temporary differences.

### 7. Trade and other receivables

	2019 £'000	Restated 2018 £'000
Trade and other receivables	1,448	1,229
Trade and other receivables from group companies	151	322
	<u>1,599</u>	<u>1,551</u>

Amounts due from group undertakings are receivable on demand, unsecured and bear interest at the Bank of England rate less a margin of 0.125%.

### 8. Trade and other payables

	2019 £'000	Restated 2018 £'000
Trade and other payables	1,017	1,102
Trade and other payables to group companies	205	225
	<u>1,222</u>	<u>1,327</u>

Amounts due to group undertakings are repayable on demand, unsecured and bear interest at the Bank of England rate plus a margin of 1.25%.

### 9. Share capital

	2019 £'000	2018 £'000
<b>Authorised, issued and fully paid:</b>		
1 (2018: 1) ordinary share of £1 each	<u>-</u>	<u>-</u>

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the Company.

On 19 December 2018, BMG Rights Management (UK) Limited subscribed to 1 Ordinary share for £250,000. This created share capital of £1 and share premium of £249,999. Subsequently a capital reduction was completed whereby 806 Ordinary shares of £1 were cancelled and the entire share premium of £249,999 was cancelled.

# Infectious Music Limited

## Notes to the financial statements (continued) Year ended 31 December 2019

### 10. Financial instruments

Exposure to credit, liquidity interest rate and currency risks arises in the normal course of the Company's business.

#### (a) Fair values of financial instruments

##### Trade and other receivables

The fair value of trade and other receivables is estimated as the present value of future cash flows, discounted at the market rate of interest at the Statement of financial position date if the effect is material.

##### Trade and other payables

The fair value of trade and other payables is estimated as the present value of future cash flows, discounted at the market rate of interest at the Statement of financial position date if the effect is material.

##### Cash and cash equivalents

The fair value of cash and cash equivalents is estimated as its carrying amount where the cash is repayable on demand. Where it is not repayable on demand then the fair value is estimated at the present value of future cash flows, discounted at the market rate of interest at the Statement of financial position date.

##### Interest-bearing borrowings

Fair value, which after initial recognition is determined for disclosure purposes only, is calculated based on the present value of future principal and interest cash flows, discounted at the market rate of interest at the Statement of financial position date.

##### Fair values

The fair values for each class of financial assets and financial liabilities together with their carrying amounts shown in the Statement of financial position are as follows:

	2019		Restated 2018	
	Carrying amount £'000	Fair value £'000	Carrying amount £'000	Fair value £'000
Trade and other receivables	1,448	1,448	1,229	1,229
Trade and other receivables from group companies	151	151	322	322
Cash and cash equivalents	-	-	-	-
Trade and other payables	(1,017)	(1,017)	(1,102)	(1,102)
Trade and other payables to group companies	(205)	(205)	(225)	(225)
	<u>377</u>	<u>377</u>	<u>224</u>	<u>224</u>

# Infectious Music Limited

## Notes to the financial statements (continued) Year ended 31 December 2019

### 10. Financial instruments (continued)

#### (b) Credit risk

##### *Financial risk management*

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers. This risk is mitigated as balances are spread across multiple parties.

The Company's principal financial assets are bank balances and trade receivables which represent the Company's maximum exposure to credit risk in relation to financial assets. The Company bears the bad debt risk on all debtors. The Company's management make assessments on new customers before work is earned out, based on their knowledge of the industry and the customer's acceptance of imposed credit terms.

The amounts presented in the Statement of financial position are net of allowances for doubtful receivables after taking into consideration the amount of balances covered by the Company's credit insurance policy. These have been estimated by the Company's management based on prior experience and their assessment of the current economic environment.

##### *Exposure to credit risk*

The carrying amount of financial assets represents the maximum credit exposure. Therefore, the maximum exposure to credit risk at the Statement of financial position date was £850,000 (2018: £423,000), being the total of the carrying amount of trade and other receivables, shown in the table above.

	2019			Restated 2018		
	Gross trade receivables £'000	Doubtful debt provision £'000	Net trade receivables £'000	Gross trade receivables £'000	Doubtful debt provision £'000	Net trade receivables £'000
Not past due	<u>1,511</u>	<u>(63)</u>	<u>1,448</u>	<u>1,276</u>	<u>(47)</u>	<u>1,229</u>

##### *Impairment of financial assets*

The Company has trade receivables for royalty licensing that is subject to the expected credit loss model.

While cash and cash equivalents are also subject to the impairment requirements of IFRS 9, the identified impairment loss was immaterial.

##### *Trade receivables and contract assets*

The Company applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables and contract assets.

#### (c) Liquidity risk

##### *Financial risk management*

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.

Liquidity is managed by the group via the cash pooling facility.

The Company's financial liabilities are shown in Note 8. All amounts are repayable within contracted terms.

# Infectious Music Limited

## Notes to the financial statements (continued) Year ended 31 December 2019

### 10. Financial instruments (continued)

#### (d) Market risk

##### *Financial risk management*

Market risk is the risk that changes in market prices, such as foreign exchange rates and interest rates will affect the Company's income or the value of its holdings of financial instruments.

##### *Market risk - Foreign currency risk*

A proportion of sales and purchases are invoiced in foreign currency and the Company bears the foreign currency risk on these debtors and creditors. The Company does not take out forward contracts on currency.

##### *Sensitivity analysis – Foreign currency risk*

A sensitivity analysis was not performed because the Company converts foreign currency bank balances into pounds sterling regularly and therefore exposure to foreign currency risk is minimal.

##### *Market risk – interest rate risk*

The Company utilises a group cash pooling facility, on which interest is charged at variable rates, based on the Bank of England base rate plus a margin of 1.25%.

The Company's exposure to interest rate risk arises from the fluctuations in the rate of interest charged on cash and cash equivalent balances payable as impacted on by the changes in the Bank of England base rate.

##### *Sensitivity analysis – interest rate risk*

A change of one percent in interest rates at the Statement of financial position date would have decreased the Company's profit by the amounts shown below. This calculation assumes that the change occurred at the Statement of financial position date and had been applied to risk exposures existing at that date.

This analysis assumes that all other variables, in particular foreign currency rates, remains constant and considers the effect of financial instruments with variable interest rates.

At the year end it is estimated that an increase of one percent in the 3 month LIBOR market rate would decrease the Company's profit before taxation by approximately £1,000 (2018: £1,000).

#### (e) Capital risk management

The Company manages its capital to ensure that entities in the group will be able to continue as going concerns while maximising the return to stakeholders through the optimisation of the debt and equity balance.



# Infectious Music Limited

## Notes to the financial statements (continued) Year ended 31 December 2019

### 11. Related parties

#### Identity of related parties

The Company's ultimate parent company and group is the international media company Bertelsmann SE & Co. KGaA.

The Company had a related party relationship in the year with subsidiaries of Bertelsmann SE & Co. KGaA, and with its directors and executive officers:

#### Related party transactions

During the year the Company entered into the following transactions with related parties. The transactions were priced on an arm's length basis.

	Sales/ (purchases) of goods		Trade balances receivable / (payable)	
	2019	2018	2019	2018
	£'000	£'000	£'000	£'000
BMG Rights Management (Canada), Inc.	7	-	-	-
BMG Rights Management (US) LLC	263	57	2	1
BMG Rights Management (UK) Limited	399	(218)	(8)	107
BMG Rights Management GmbH	31	1	30	1
BMG Rights Management (Scandinavia) AB	-	1	-	1
BMG Rights Management (Spain), S.L	4	-	-	1
BMG AM Pty Limited	-	1	-	1
BMG Rights Management (Benelux) B.V	-	2	-	2
BMG Rights Management (Italy) S.R.L	-	10	9	10
BMG Rights Management Services (UK) Limited	(511)	(319)	(88)	(27)
	<u>193</u>	<u>(465)</u>	<u>(55)</u>	<u>97</u>

## **Infectious Music Limited**

### **Notes to the financial statements (continued)** **Year ended 31 December 2019**

#### **12. Ultimate parent company and controlling party**

The immediate parent company is BMG Rights Management (UK) Limited, a company incorporated in the United Kingdom. The ultimate parent company is Bertelsmann SE & Co. KGaA.

The results of the Company are included in the consolidated financial statements of Bertelsmann SE & Co. KGaA which is registered at Carl-Bertelsmann-Strasse 270, 33311 Gütersloh, Germany. These consolidated financial statements are publicly available.

No other group financial statements include the results of the Company.